Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) EBITDA Margin: 2020-2025

Historic EBITDA Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -67,983.33%.

  • 4D Molecular Therapeutics' EBITDA Margin rose 163641667.00% to -67,983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -191,982.50%, marking a year-over-year increase of 79846456.00%. This contributed to the annual value of -507,678.38% for FY2024, which is 50713373.00% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EBITDA Margin is -67,983.33%, which was up 82.85% from -396,373.33% recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' EBITDA Margin registered a high of 192,905.26% during Q4 2023, and its lowest value of -5,611,700.00% during Q4 2024.
  • For the 3-year period, 4D Molecular Therapeutics' EBITDA Margin averaged around -816,317.86%, with its median value being -136,200.00% (2024).
  • As far as peak fluctuations go, 4D Molecular Therapeutics' EBITDA Margin slumped by 580,460,526bps in 2024, and later surged by 163,641,667bps in 2025.
  • 4D Molecular Therapeutics' EBITDA Margin (Quarterly) stood at -26,917.39% in 2021, then skyrocketed by 2,461,426bps to -2,303.13% in 2022, then soared by 19,520,839bps to 192,905.26% in 2023, then slumped by 580,460,526bps to -5,611,700.00% in 2024, then skyrocketed by 163,641,667bps to -67,983.33% in 2025.
  • Its last three reported values are -67,983.33% in Q3 2025, -396,373.33% for Q2 2025, and -383,007.14% during Q1 2025.